Compare Johnson & Johnson (JNJ) vs Nebius Group NV (NBIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Nebius Group NV — how do they compare? Johnson & Johnson trades at $248.97 (market cap $609.12B), while Nebius Group NV trades at $187.53 (market cap $45.12B). The key difference: Johnson & Johnson is far larger — about 13.5× Nebius Group NV's market cap, and Johnson & Johnson pays a 2.12% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.
| JNJ | NBIS | |
|---|---|---|
Market Cap | $609.12B | $45.12B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $286.69 |
52-Week Low | $163.70 | $50.40 |
Enterprise Value | $642.06B | $45.32B |
Dividend Yield | 2.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
NBIS trades at $182.62, up 2.76% today, with a bullish technical signal despite recent volatility. The company reported Q1 2026 EPS of -$0.23, beating expectations, and secured a $775 million debt facility to accelerate AI cloud expansion. Analyst consensus remains strongly positive with an $242 price target, though high valuation ratios (P/E 68.61, P/S 53.73) reflect growth expectations.
Outlook is supported by robust AI demand and a debt-free balance sheet, but risks include intense competition and execution challenges in scaling infrastructure. The stock offers significant upside if growth targets are met, yet remains sensitive to sector sentiment shifts and capital expenditure pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
